The acquisition of Azora and the $32M financing mark a fundamental shift in Adial's story from addiction to inflammatory disease. The key catalyst to watch is the IND filing for AT177 in H1 2027 and any data readouts from the Phase 1 program. The additional $32M milestone tranche is a potential near-term positive if triggered. Monitor for stockholder approval of the Series A conversion, which would reclassify $38.5M from mezzanine to equity and eliminate a major balance-sheet overhang.
Price Chart
Executive Summary
Adial Pharmaceuticals reported Q2 2026 results highlighting a strategic pivot via the acquisition of Azora Therapeutics (adding AT177 for ulcerative colitis) and a $32M initial tranche of a $64M private placement. The quarter featured a massive GAAP net loss of $52.0M ($11.25/share) driven by a $46.2M non-cash acquired IPR&D charge, but cash increased to $28.7M, extending runway into H2 2027. The filing is a transformative business update, not a standard earnings report, with the core value driver being the new pipeline asset and strengthened balance sheet.
Key Financial Metrics
Key Facts
- Completed acquisition of Azora Therapeutics, adding AT177, an oral AhR agonist for ulcerative colitis.
- Closed initial $32M tranche (including $5.5M note conversion) of an up to $64M private placement from biotech specialist investors.
- Cash and cash equivalents of $28.7M as of June 30, 2026, up from $4.6M as of March 31, 2026.
- Net loss of $52.0M ($11.25/share) for Q2 2026, compared to $2.0M ($4.61/share) in Q2 2025, primarily due to a $46.2M non-cash acquired IPR&D charge.
- IND filing for AT177 planned for H1 2027, with Phase 1a SAD/MAD trial expected to commence in H2 2027.
- Company believes existing cash funds operations into H2 2027, excluding the additional $32M milestone tranche.
- Stockholders' Deficit of ($38.4M) due to $23.8M milestone warrant liability and $38.5M mezzanine equity from Series A preferred stock.
Financial Impact
Cash increased by $24.1M sequentially to $28.7M; net loss of $52.0M includes a $46.2M non-cash charge; operating cash burn not explicitly stated but R&D spend was $440K and G&A was $5.4M.
Risk Factors
- AT177 is still in IND-enabling studies; clinical failure or regulatory delays would reset the pipeline.
- The $46.2M IPR&D charge signals the acquired asset had no alternative future use, a binary bet on AT177's success.
- Stockholders' Deficit of ($38.4M) and pending stockholder approval for Series A conversion create balance-sheet uncertainty.
- Nasdaq listing risk noted in forward-looking statements; company intends to file an initial listing application.
- The additional $32M milestone tranche is not guaranteed and depends on achieving specific milestones.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-090482 |
| Document: ea030196601ex99-1.htm | 0001213900-26-090482 |
| Document: 0001213900-26-090482-index-headers.html | 0001213900-26-090482 |
| Document: 0001213900-26-090482-index.html | 0001213900-26-090482 |
| Document: 0001213900-26-090482.txt | 0001213900-26-090482 |
| 8-K Data (Synthetic) | 0001213900-26-090482 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | EFFECT | $3.68 | awaiting T+60 | — | $3.88 (−5.43%) |
Oct 20, 2026 6d ago | 10-Q/A | $4.11 | awaiting T+60 | — | $3.88 (+5.60%) |
Oct 20, 2026 6d ago | S-3/A | $4.11 | awaiting T+60 | — | $3.88 (+5.60%) |
Oct 16, 2026 10d ago | DEFA14A | $3.62 | awaiting T+60 | — | $3.88 (−7.18%) |
Oct 16, 2026 10d ago | 8-K | $3.62 | awaiting T+60 | — | $3.88 (−7.18%) |
Sep 30, 2026 26d ago | Press Release | $4.13 | awaiting T+60 | — | $3.88 (−6.05%) |
Sep 18, 2026 5w ago | DEFA14A | $4.40 | awaiting T+60 | — | $3.88 (−11.82%) |
Sep 18, 2026 5w ago | 8-K | $4.40 | awaiting T+60 | — | $3.88 (−11.82%) |
Sep 16, 2026 5w ago | DEFA14A | $5.21 | awaiting T+60 | — | $3.88 (−25.53%) |
Sep 16, 2026 5w ago | 8-K | $5.21 | awaiting T+60 | — | $3.88 (−25.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers